Mercy BioAnalytics, Inc.

Mercy BioAnalytics, Inc. is a biotechnology company focused on developing highly accurate, low-cost, and accessible blood-based tests for early cancer detection. Their patented Mercy Halo™ platform utilizes extracellular vesicles (EVs), naturally occurring particles released by all cells, to identify cancer-associated biomarkers. Unlike traditional liquid biopsy approaches that rely on circulating tumor DNA (ctDNA), which can be scarce in early-stage cancers, Mercy Halo leverages the abundance and stability of EVs to detect multiple co-localized biomarkers with high sensitivity and specificity.

Mercy's initial focus is on developing tests for ovarian and lung cancer, two cancers often diagnosed at late stages when treatment options are limited. The company is driven by a mission to save lives and relieve suffering through early cancer detection, and their team is dedicated to rigorous scientific research and development, evidenced by their numerous publications and presentations at prestigious scientific conferences. Mercy has received Breakthrough Device Designation from the FDA for their ovarian cancer screening test, demonstrating its potential to significantly impact patient outcomes.

Mercy BioAnalytics offers flexible work arrangements for its employees, including the option to work on-site, hybrid, or remotely. This flexibility allows employees to choose the work environment that best suits their individual needs and preferences. The company also offers a part-time opportunity for the Chief Medical Officer position, demonstrating a commitment to accommodating diverse work styles.

Mercy BioAnalytics is a biotechnology company dedicated to saving lives and relieving suffering through the early detection of cancer. The company utilizes its patented Mercy Halo™ platform, which analyzes extracellular vesicles (EVs) in blood, to develop highly accurate, low-cost, and broadly accessible tests capable of detecting cancer at its earliest stages, when it is most treatable. Mercy prioritizes rigorous science and focuses on developing tests for a variety of cancers, including ovarian and lung cancer, which often go undetected until later stages when treatment options are limited.

Mercy BioAnalytics promotes a culture of collaboration, humility, and a relentless focus on its mission of saving lives through early cancer detection. They value evidence-driven solutions, regardless of origin, and encourage bold ambition grounded in rigorous science. They prioritize teamwork and inclusion, championing a "yes, then explore the how" mentality, fostering an environment of fearless curiosity and continuous improvement.

Mercy BioAnalytics is committed to building a diverse and inclusive workplace, valuing ideas and evidence-driven solutions regardless of their origin. They believe in creating an environment where everyone feels welcome, respected, and empowered to contribute their unique perspectives and talents. The company's commitment to diversity, equity, and inclusion extends beyond their internal culture, influencing their interactions with partners, customers, and the communities they serve.